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Background: Up to 42% of all stroke patients do not get out of the house as much as they would like. This can
impede a person’s quality of life. This study is testing the clinical effectiveness and cost effectiveness of a new
outdoor mobility rehabilitation intervention by comparing it to usual care.
Methods/design: This is a multi-centre parallel group individually randomised, controlled trial. At least 506
participants will be recruited through 15 primary and secondary care settings and will be eligible if they are over
18 years of age, have had a stroke and wish to get out of the house more often. Participants are being randomly
allocated to either the intervention group or the control group. Intervention group participants receive up to 12
rehabilitation outdoor mobility sessions over up to four months. The main component of the intervention is
repeated practice of outdoor mobility with a therapist. Control group participants are receiving the usual
intervention for outdoor mobility limitations: verbal advice and provision of leaflets provided over one session.
Outcome measures are being collected using postal questionnaires, travel calendars and by independent assessors.
The primary outcome measure is the Social Function domain of the SF36v2 quality of life assessment six months
after recruitment. The secondary outcome measures include: functional ability, mobility, the number of journeys
(monthly travel diaries), satisfaction with outdoor mobility, mood, health-related quality of life, resource use of
health and social care. Carer mood information is also being collected.
The mean Social Function score of the SF-36v2 will be compared between treatment arms using a multiple
membership form of mixed effects multiple regression analysis adjusting for centre (as a fixed effect), age and
baseline Social Function score as covariates and therapist as a multiple membership random effect. Regression
coefficients and 95% confidence intervals will be presented.
Discussion: This study protocol describes a pragmatic randomised controlled trial that will hopefully provide robust
evidence of the benefit of outdoor mobility interventions after stroke for clinicians working in the community. The
results will be available towards the end of 2012.
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Stroke can have a devastating effect on people's lives,
with half of survivors being dependent on others six
months later [1], one third feeling socially isolated, one
quarter having abnormal mood and half not getting out
of their house as much as they would like. These are
worldwide health care issues which affect many people.
A total of 130,000 people a year have a stroke in England
and Wales (Office of National Statistics 2001). Commu-
nity based research over the last three decades has
shown that people living at home with stroke have felt
neglected, not provided with the correct information
and have received patchy levels of rehabilitation [2]. The
NHS has developed guidelines through the National Ser-
vice Framework for Older People [3] and the National
Clinical Stroke Guidelines [4] to help commissioners
and therapists provide evidence-based practice. How-
ever, within these documents there is very little informa-
tion about the long-term rehabilitation that should be
provided because the research evidence is not available
to help make robust recommendations.
A single centre randomised controlled trial which eval-
uated an outdoor mobility rehabilitation intervention
found clear outdoor mobility benefits for those people
who received the intervention [5]. The generalisability of
the study was limited as the intervention was delivered
by a single therapist, in one city and there was no eco-
nomic evaluation. Our single centre trial provided con-
firmation that we were asking a relevant and important
question and that the intervention could be implemen-
ted within existing NHS structures. This present multi-
centre trial was planned to evaluate the clinical and
economic effectiveness of the intervention before we can
recommend its wider adoption.
Methods/design
Trial purpose
The trial’s purpose was to confirm or refute the clinical
effectiveness and cost effectiveness of treating stroke
patients with outdoor mobility limitations with a novel
targeted rehabilitation therapy intervention versus stand-
ard clinical practice.
Trial objectives
The health care objective is to improve the quality of
people’s lives after a stroke by enabling them to get out
of the house more often and when they wish.
The research objective is to test the effectiveness and
cost effectiveness of treating people who have had a stroke
with a new outdoor mobility rehabilitation intervention.
Trial design
This is a multi-centre parallel group randomised, con-
trolled trial. The trial consists of an initial baseline visit toprovide information and explain the study, take informed
consent, provide the routine clinical stroke rehabilitation
treatment, complete a set of questionnaires and provide a
travel diary with instructions. Randomization to the con-
trol or intervention group is stratified by age (<65 years
and ≥65 years) and site. The intervention group are re-
ceiving up to 12 intervention visits within four months
from recruitment. All participants are completing monthly
travel diaries and questionnaires at 6 and 12 months.Site and participant recruitment
We planned to have 15 NHS community or Primary or
Secondary Care Trust study sites throughout England,
Scotland and Wales. People who have had a stroke were
identified between November 2009 and July 2011
through GP practices, primary care therapy teams and
community stroke teams. A letter along with study in-
formation was sent to the identified stroke patients by a
member of their normal clinical care team, asking if they
were interested in taking part in the study. The letter
contained a reply slip and a reply paid envelope. If the
potential participant was interested in taking part, they
completed the slip and returned it in the envelope dir-
ectly to the local stroke/therapy team, who then
informed the local Research Assistant (RA). The RA
then contacted the patient to arrange an appointment to
discuss the study further and respond to any questions.
If needed, an interpreter, translator or signing service
was available. The RA explained the details of the trial
and provided a Participant Information Sheet, ensuring
that the participant had sufficient time to consider
whether or not to participate.Informed consent
It was explained to the potential participant that their
entry into the trial was entirely voluntary and that their
treatment and care would not be affected by their deci-
sion. It was also explained that they could withdraw at
any time. In the event of their withdrawal, it was
explained that their data collected so far could not be
erased and would be used in the final analyses. If they
agreed to participate in the study, the RA asked the par-
ticipant to give written consent before they underwent
any interventions related to the study that would not
have formed part of their normal care. Those partici-
pants unable to sign the consent form were asked to
mark the form and a witness (either Carer or other per-
son present) also signed the relevant section on the con-
sent form. One copy was kept by the participant, one by
the Investigator, and a third retained in the patient’s GP
records. With the consent of the participant the research
team informed the participant's GP about their partici-
pation in the clinical trial.
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Patients were eligible for the study if they provide writ-
ten informed consent and if they: (i) are aged 18 years or
over; (ii) have had a stroke at least 6 weeks previously
and (iii) wish to get out of the house more often.
Exclusion criteria
Patients were not eligible for the study if they: (i) were
not able to comply with the requirements of the proto-
col and therapy program, in the opinion of the assessor;
(ii) still in post-stroke intermediate care or active re-
habilitation or (iii) were previously enrolled in this study.
Outcome measures
Baseline
The RA collected basic demographics required for ran-
domisation from each participant at the baseline visit.
The baseline assessment questionnaires were completed
while the RA was present and returned to the trial co-
ordinating centre. The basic demographics, including
the NHS number were recorded and supplied to the
NHS IC/NHS Central Register to allow mortality checks
prior to follow-up.
Assessment questionnaires
The 6- and 12-month assessment questionnaires are
being posted to the participants along with reply paid
envelopes. If the assessments have not been returned
within 2 to 3 weeks of the 6- or 12-month timeline then
the participant is contacted by telephone by a member
of the research team to remind them. Finally, if two to
three weeks later the assessments have still not been
returned, then the blinded-to-intervention RA arranges
to visit the participant and assist in completing the ques-
tionnaires. Using this method, a 90% return rate of ac-
tive participants (that is, those which had not
withdrawn, died or been lost to follow-up) was found in
the previous single centre trial with the further 10% col-
lected by an independent assessor.
Travel diaries
A travel diary is being completed by all participants on a
monthly basis. This is in the form of a calendar with the
participants entering the number of journeys made on
the calendar for that particular day. In addition, in order
for the study team to assess safety, participants indicate
when they have had a fall on a particular day. The par-
ticipant is provided with 12 calendar months’ worth of
travel diary. Training is provided at baseline assessment
in the completion and return of the travel diaries. At the
end of each month participants are asked to return that
month of the calendar to the research team. A reminder
letter is sent to the participant, along with a reply paidenvelope, a short time before the previous month’s diary
is due for return.
Primary outcome measure
The social function domain score of the SF-36v2 [6]
measured at six months. This is one of the eight
domains of the SF-36v2 and is scored and transformed
on to a scale 0 (worst possible health state) to 100 (best
possible health state).
The secondary outcome measures at 6 and 12 months
are: (i) Nottingham Extended Activities of Daily Living
Scale [7] (a measure of functional ability). (ii) Rivermead
Mobility Index (a measure of mobility) [8]. (iii) Travel
Diary (number of journeys). (iv) Yes or no question: "Do
you get out of the house as much as you would like?"
(Satisfaction with outdoor mobility). (v) General Health
Questionnaire 12 (GHQ-12) [9] (measure of participant
mood). (vi) GHQ-12 [9] (measure of Carer mood).(vii)
EQ-5D [10] and SF-6D (subset of SF-36 v2 [6]) (viii) Re-
source use of health and social care and provision of
equipment. (ix) Participant mortality (death data) will be
collected from NHS IC/NHS Central Register.
Carer assessment
Part of the study is to assess if any benefits to the parti-
cipants are allied with benefits to their carer. For this
study, the definition of a carer is “someone who provides
unpaid care by looking after a family member, friend or
partner following stroke”. In order to assess this, we are
asking the carer, if applicable, to complete the GHQ-12
questionnaire at baseline, 6 months and 12 months. The
RA first asks the participant if they would like their carer
to be asked about completing this questionnaire. We
provide a carer information sheet, though we do not ask
them to provide informed consent as completion of the
questionnaire will be seen as implied consent. This is
explained to the carer.
Health economics
The consequences in terms of patient-specific resource
use will be measured using responses to the 6- and 12-
month assessments; this will capture information on
quantity of primary and secondary health care use, use
of personal social services and some patient/carer costs.
Unit costs will be derived from routine published cost
data sources, such as the PSSRU health and social care
costs [11] and NHS Reference Costs [12] using a com-
mon price year. This will enable the overall management
cost of treatment to be calculated for each patient and,
in turn, the incremental mean cost associated with the
intervention compared to control to be estimated. A cost
utility analysis will be undertaken measuring health-
related quality of life using both the EuroQol EQ-5D
[10] and SF-6D [6].
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Randomisation is based on a computer generated
pseudo-random code using random permuted balanced
blocks of randomly varying size, created by the Notting-
ham Clinical Trials Unit (NCTU) in accordance with
their standard operating procedure (SOP) and held on a
secure server. The randomisation is stratified by age
(<65 years and ≥65 years) and site. Sixty-five years of
age was chosen because Mobility Allowance, a monetary
allowance is only available under this age and is often
used to purchase a car. This is not available for people
over 65 years of age. All participants are given the con-
trol group standard information prior to randomization
in order to minimize performance bias and reduce con-
tamination. Participants are randomly allocated (1:1
ratio) to either the intervention or to the control group.
Access to the sequence is confined to the NCTU Data
Manager (who is independent from the study team).
Investigators/sites access the treatment allocation for
each participant by means of a remote, secure, internet-
based randomisation system developed and maintained
by the NCTU. The sequence of treatment allocations is
concealed until interventions have all been assigned and
recruitment, data collection and all other trial-related
assessments are complete. After confirming study eligi-
bility and obtaining informed consent, the investigator
enters basic demographic details into the web-based
randomization program. Once these details have been
entered irrevocably into the program, the group to
which the patient is randomly allocated is provided to
the investigator.
Minimization of bias and maximising blinding
We have taken every step to maintain blinding for the
outcome assessments by using postal questionnaires and
RAs. Following any visits, at 6 and 12 months, to assist
with questionnaire completion, the RA completes a
blinding questionnaire to assess if the blinding has been
broken. The data are entered, stored and managed by
the NCTU until the end of the trial. We are recruiting
participants from numerous sites across the UK to re-
duce response bias and we are using numerous rehabili-
tation staff to reduce expertise bias.
Maintenance of randomisation codes and procedures for
breaking code
Neither the participants nor the therapist are blinded to
which treatment the participants receive. The RA is
blind, though there is no foreseeable situation whereby
they would need to know the treatment allocation of a
particular participant. The outcome assessors are blind,
but again there is no requirement for them to know the
treatment allocation at any stage. As a result there is no
procedure in place for breaking the randomisation code.The statistician analysing the data is also blind and allo-
cations will not be revealed until all data analyses have
been completed.
Duration of the trial
The recruitment phase of the trial is estimated to last a
total of three years, from initiation of the first site to
completion for the last patient. This commenced in No-
vember 2009. For any given participant the duration of
their involvement will be a minimum of 12 months to a
maximum of 14 months. Participants’ involvement in
the trial will end when they have completed and
returned the 12-month assessment questionnaires and
travel diary.
End of the trial
The end of the trial is defined as completion and return
of the 12-month assessment questionnaires, scheduled
to occur within 2 months after the 12-month assessment
date of the last participants.
Removal of participants from therapy or assessments
No specific withdrawal criteria have been defined for this
study. If a participant leaves the study prematurely (that
is, prior to completion of the protocol), the primary rea-
son for discontinuation will be determined and recorded,
if at all possible. Withdrawn participants are not being
replaced. Anonymity of participants will be assured.
The interventions
A novel rehabilitation technique (intervention) group
will be compared to a usual care (control) group.
Intervention group
Participants receive what is considered clinically to be
routine intervention for outdoor mobility limitations.
That is, verbal advice and provision of leaflets provided
during the baseline assessment visit. In addition, partici-
pants in this group receive up to 12 rehabilitation out-
door mobility sessions of about an hour each over four
months. Development of this intervention followed the
guidelines for complex interventions [13] using qualita-
tive research findings [14] in the pre-clinical stage to de-
velop ‘barriers and need’ theories. The intervention aims
to increase outdoor mobility participation by alleviating
physical difficulties, develop skills to maximize the indi-
vidual's potential and to overcome psychological bar-
riers. A description of the intervention has been
published [15]. The main component of the intervention
is that therapists go repeatedly with patients to try out-
door mobility, including buses, taxis, walking, voluntary
drivers and mobility scooters until they feel confident to
go alone or with a companion. The number of interven-
tions depends entirely on the participant. If they feel
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ever reason, then the interventions can stop. If they feel
they require additional intervention, for whatever rea-
son, they can continue the intervention, up to a max-
imum of 12 visits.Control group
Participants receive what is considered clinically to be
routine intervention for outdoor mobility limitations.
That is, verbal advice and provision of leaflets provided
during the baseline assessment visit.Sample size and justification
We intend to recruit 506 participants, 253 into each arm.
Our sample size calculations are based on the primary
outcome measure, the Social Function domain of the
Short Form 36 version 2 (SF-36v2) at six-month follow-
up. A recent study suggested a minimally, clinically im-
portant difference (MCID) for the social function domain
is 12.5 points [16]. Assuming a power of 90% and a two-
sided significance level of 5%, we estimate that to detect a
difference in mean SF-36v2 scores of 12.5 points assum-
ing a common standard deviation of 28.2 [17], a sample
size of 135 patients per arm is required. This calculation
assumes an attrition rate of 20% over the six-month
period. Clustering by delivery of treatment was allowed
for, using an ICC of 0.02 (obtained from a personal com-
munication from Walters) and a centre effect ICC of 0.04
(obtained from Aberdeen University’s database of ICCs
(http://www.abdn.ac.uk/hsru/epp/iccs-web.xls)).
Originally, we calculated our total sample size, which
was 676 participants, using the same procedure as above
but with seven sites. Due to recruitment being slower
than anticipated, we extended the recruitment period
and increased the number of centres to 15. Revised sam-
ple size calculations were based on a number of scenar-
ios. These calculations indicated that a sample size of
440 would have a power of 86% (assuming no attrition)
and a power of 82% (assuming an attrition rate of 20%)
to detect a difference in means of 12.5 on the Social
Function domain of the Short Form 36 version 2 (SF-
36v2) at six-month follow-up if there were 7 centres
and, if there were 12 or more centres, the corresponding
power would be at least 90% if an attrition rate of 20%
was assumed. By increasing the number of centres to 15
we were able to use the later calculations.
Our sample size calculations were based on a number
of assumptions and although we used the best estimates
we could obtain there was some uncertainty about the
true values of the ICCs used to adjust for clustering. We,
therefore, decided to be cautious and aimed to recruit a
sample size of 506 (440 +15%) to ensure we recruited
enough participants.Statistical analysis
Data are stored in a Microsoft Access Database and ana-
lyzed using the statistical package STATA (StataCorp,
Texas, USA). Paper records are kept in a locked cabinet,
separate from any identifiable information, such as the
consent forms. A full data analysis plan has been pro-
duced and agreed with the Trial Steering Group. Out-
come measures are recorded at 6 and 12 months but the
primary time point of interest is 6 months. However, this
data will not be analysed until all study data have been
collected. The study report will be produced according
to the CONSORT recommendations [18].
Descriptive analyses
Continuous data that are approximately, normally dis-
tributed will be summarised in terms of the mean,
standard deviation and the number of observations.
Skewed data will be presented in terms of the median,
lower and upper quartiles, minimum, maximum and
number of observations. Categorical data will be sum-
marised in terms of frequency counts and percentages.
Comparisons between treatment arms
Analyses will be undertaken on an intention to treat
basis in that participants will be analysed in the group to
which they were randomised regardless of whether they
received the intervention or not. Two-sided tests will be
used to test statistical significance at the 5% level.
Assessment of efficacy
Analysing primary outcomes
The mean Social Function score of the SF-36v2 will be
compared between treatment arms using a multiple
membership form of mixed effects, multiple regression
analysis adjusting for centre (as a fixed effect), age and
baseline Social Function score as covariates and therap-
ist as a multiple membership random effect. Regression
coefficients and 95% confidence intervals will be pre-
sented. The robustness of these findings will be assessed
by repeating the analysis and including baseline variables
(such as gender) that are associated with the outcome
variable as covariates in the model.
Analysing secondary outcomes
The outcome variables mobility measured with the Riv-
ermead Mobility Index [8] number of outdoor journeys
taken, functional ability measured by the Nottingham
Extended Activities of Daily Living Scale [19]; mood and
carer psychological distress measured by the General
Health Questionnaire 12 [9] will be analysed using the
same method as for the primary outcome measure. In all
analyses, an adjustment for centre, therapist effect, age
and baseline value will be made.
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the house as often as they would like will be compared
between treatment arms using a mixed effects logistic
regression analysis adjusting for centre (as a fixed effect),
age and whether or not they get out of the house as
often as they would like as recorded at baseline. Odds
ratios and 95% confidence intervals will be presented.
The robustness of the findings for all secondary out-
comes will be assessed by repeating the analysis and in-
cluding baseline variables, (such as gender), that are
associated with the outcome variable as covariates in the
model.
We acknowledge the potential for type 1 errors asso-
ciated with significance testing for multiple end points.
We will, therefore, consider our analyses of the second-
ary outcome measures to be partly exploratory in nature,
and partly confirmatory of our findings for the primary
outcome measure.
Health economic evaluation
An economic evaluation will be a major element of the
project. This component of the study aims to extend the
evidence base by estimating for the first time the incre-
mental cost-effectiveness of an outdoor mobility re-
habilitation intervention, compared to usual care, from a
health and personal social services perspective for the
trial period. In addition, the patient and carer perspec-
tive will be examined separately.
The EQ-5D includes five pertinent dimensions, (ability
to perform usual activities, mobility, anxiety and depres-
sion, pain and self-care), each with three levels of severity
(no problems, some/moderate problems and severe/ex-
treme problems). Responses to these five dimensions will
be converted into one of 243 different EQ-5D health state
descriptions, which range between no problems on all five
dimensions (11111) and severe/extreme problems on all
five dimensions (33333). We will use the York A1 tariff to
assign a utility score to each of these states. The SF-6D is
measured using the responses to 11 of the questions on
the SF-36 questionnaire for use in cost utility analyses
[20]. The SF-6D is composed of six dimensions (physical
functioning, role limitations, social functioning, pain,
mental health and vitality), which have between four and
six severity levels. It, thereby, has 18,000 potential health
states and scores for these states have been estimated [6].
Both measures are being used at baseline, 6 and
12 months. Quality Adjusted Life Year (QALYs) will be
estimated over the trial period between the comparator
interventions in order to provide a cost per QALY for the
getting out of your house intervention. As a generic meas-
ure of outcome this analysis will enable the results to be
compared to that of other economic evaluations for stroke
and other conditions, in order to assess whether allocation
of resources to a getting out of the house interventionoffers value for money compared to other potential uses
of the resources.
As the EQ-5D and SF-6D utility measures are based
on both different health state descriptions, and use dif-
ferent valuation techniques, they can produce different
utility scores for the same group of patients. This study
will seek to investigate which of these two outcome mea-
sures is appropriate using certain published criteria and
to explore the impact choice of utility measure has on
estimates of cost-utility since further research has been
argued as justified in these areas.
Although not anticipated, censored data will be
adjusted using appropriate published techniques [21]
should this be necessary. If non-dominance occurs (that
is, if costs are greater and the intervention is more ef-
fective or if the intervention is cheaper and less effective)
an incremental cost-effectiveness ratio (the ratio of
change in cost divided by change in benefit) will be pro-
duced. The confidence region around the incremental
cost effectiveness ratio will be estimated using appropri-
ate statistical techniques, such as the non-parametric
bootstrap method. This stochastic analysis will enable a
cost effectiveness acceptability curve to be produced il-
lustrating the uncertainty surrounding the optimal deci-
sion. Probabilistic sensitivity analysis will be undertaken
to test the robustness of the results. Estimates of the in-
cremental cost, incremental costs effectiveness and the
uncertainty around these estimates will enable us to
examine whether "The getting out of the house interven-
tion" offers value for money.Fidelity of treatment
The rehabilitation staff providing the treatment are com-
pleting an intervention record for each participant and
recording number and duration of treatment. These
records are monitored against a predefined checklist to
make sure the intervention is being delivered according
to the protocol. In addition, a selection of therapy visits
are observed and scored against a predefined checklist.Assessment of safety and adverse events
The main risk associated with this intervention is an
increased risk of falling, as participants are being
encouraged to become more mobile. So, as all falls will
be self-reported on the travel diary, the only adverse
events we will record will be any falls within the inter-
vention group that required the assistance of a health-
care professional. To capture these events the therapist
will ask, subsequent to the first visit, “Have you had any
falls since my last visit?” The occurrence of a serious ad-
verse event as a result of participation within this study
is not expected so no serious adverse event data will be
collected.
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Any participant who experiences an adverse event may
be withdrawn from the study at the discretion of the
Investigator.
Procedures for missing, unused and spurious data
Initially a complete case analysis will be performed for
the primary and secondary outcome measures and a sen-
sitivity analysis will then be performed in which missing
dependent and independent variable data will be replaced
using multiple imputations. Missing data will be imputed
separately for the intervention and control groups.
Compliance
Compliance in this trial will be completion and return-
ing of all diaries and questionnaires. In practice this
means 12 monthly travel diaries and three sets of assess-
ment questionnaires, one each at baseline, 6 months and
12 months.
Criteria for terminating trial
The study may be stopped as a whole because of a change
in opinion of the REC or overwhelming evidence of effi-
cacy/inefficacy, safety concerns or issues with trial conduct
at the discretion of the Sponsor. Recruitment at a centre
may be stopped particularly for reasons of low recruit-
ment, protocol violation or inadequate data recording.
Trial management
The trial will be managed by the Trial Management
Group. The Trial Steering Committee and Data Moni-
toring Committee will be combined as a risk assessment
has been completed and as the risk to participants is low
we consider that the two committees will work best if
they are merged. This will be called the Trial Steering
and Data Committee (TSDC). The TSDC will meet in-
dependently prior to the start of the study and will agree
to terms of reference and will monitor unblinded data
and the conduct of the study. Only the TSDC will have
access to unblinded data until the final outcome assess-
ment has been completed. The TSDC will recommend
discontinuation of the study if significant ethical or
safety concerns arise or if there is very clear evidence of
benefit (clinical or statistical) prior to completion of the
study. The sponsor is the University of Nottingham,
which will clarify with the funding body (the HTA) and
local centre research and development departments their
precise responsibilities. The CI, delegated by the Spon-
sor, is responsible for the proper conduct and manage-
ment of the trial.
Definition of a protocol deviation
A protocol deviation is an unanticipated or unintentional
divergence or departure from the expected conduct of astudy inconsistent with the protocol, consent document
or other study procedures. Violations of eligibility criteria
and other deviations from protocol will be assessed by
TMG and discussed with the TSC during study evaluation
meeting before data lock and unblinding.
This summary paper is based on version 6.0, 11 Febru-
ary 2011. A copy of the full protocol is available on
request.
Trial status
Participant follow-up is on-going. Final follow-up is the
end of August 2012.
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